Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646928 | 0.87 | PLAU (0.51) | HDAC6PLAUF2F10PRSS1 | |
| SCHEMBL5645666 | 0.86 | HDAC6 (0.52) | HDAC6CYP2C19PLAUTDP1F2 | |
| SCHEMBL5649898 | 0.85 | TDP1 (0.50) | HDAC6PLAUTDP1F2F10 | |
| SCHEMBL5646339 | 0.85 | HDAC6 (0.51) | HDAC6CYP2C19PLAUTDP1F2 | |
| SCHEMBL5649877 | 0.85 | HDAC6 (0.51) | HDAC6CYP2C19PLAUTDP1F2 | |
| SCHEMBL5647425 | 0.84 | HDAC6 (0.51) | HDAC6CYP2C19PLAUF2F10 | |
| SCHEMBL5647534 | 0.84 | HDAC6 (0.58) | HDAC6CYP2C19PLAUF2F10 | |
| SCHEMBL5644813 | 0.81 | HDAC6 (0.50) | HDAC6CYP2C19TDP1F2F10 | |
| SCHEMBL5647162 | 0.81 | TDP1 (0.48) | HDAC6PLAUTDP1F2F10 | |
| SCHEMBL5652582 | 0.81 | TDP1 (0.48) | HDAC6PLAUTDP1F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199146-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | disclosed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | disclosed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SERPINC1, F2, BDKRB1 | HDAC6 172/4885CYP2C19 62/4885PLAU 112/4885 |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SERPINC1, F2, BDKRB1 | HDAC6 501/4885CYP2C19 60/4885PLAU 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.